Concepedia

Jürgen Schanzer

JS

Statistics

Publications

6

Citations

770

H-Index

6

Active since

2004

Affiliations

Roche Pharma AG (Germany)(Current)

Roche (Switzerland)

Jürgen Schanzer is an author at Roche Pharma AG (Germany) specializing in bispecific antibodies, bispecific antibody combinations, and pharmacy.

Publications per year

2004–2023

6

Publications

6

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

Wolfgang Schäfer, Jörg T. Regula, Monika Bähner et al. · Proceedings of the National Academy of Sciences · 2011 · 479 citations · Full text

Pharmacy, Biotechnology, Molecular Biology +17

Design, Synthesis, and Characterization of a Series of Cytochrome P<sub>450</sub>3A-Activated Prodrugs (HepDirect Prodrugs) Useful for Targeting Phosph(on)ate-Based Drugs to the Liver<sup>§</sup>

Mark D. Erion, K. Raja Reddy, Serge H. Boyer et al. · Journal of the American Chemical Society · 2004 · 160 citations

Medicine, Medicinal Chemistry, Pharmacology +17

Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains

Jürgen Schanzer, Andreas Jekle, Jun‐ichi Nezu et al. · Antimicrobial Agents and Chemotherapy · 2011 · 62 citations · Full text

Pharmacy, Biochemistry, Biotechnology +17

TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations

Raffaella Castoldi, Jürgen Schanzer, Christian Panke et al. · Protein Engineering Design and Selection · 2016 · 27 citations · Full text

Pharmacy, Cancer Biology, Oncology +17

Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2

Werner Scheuer, Markus Thomas, Johannes Sam et al. · mAbs · 2016 · 23 citations · Full text

Medicine, Cancer Biology, Oncology +17

1–5 of 6